These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 9617787)

  • 101. Relationship between plasma and cerebrospinal fluid norepinephrine and dopamine metabolites in a nonhuman primate.
    Greene KA; Faull KF
    J Neurochem; 1989 Oct; 53(4):1007-13. PubMed ID: 2769251
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Cerebrospinal fluid cyclic guanosine 3'5' monophosphate levels in Parkinson's disease.
    Navarro JA; Jiménez-Jiménez FJ; Molina JA; Benito-León J; Cisneros E; Gasalla T; Ortí-Pareja M; Tallón-Barranco A; de Bustos F; Arenas J
    J Neurol Sci; 1998 Feb; 155(1):92-4. PubMed ID: 9562329
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Somatostatin-like immunoreactivity, its molecular forms and monoaminergic metabolites in aged and demented patients with Parkinson's disease--effect of L-Dopa.
    Strittmatter M; Hamann GF; Strubel D; Cramer H; Schimrigk K
    J Neural Transm (Vienna); 1996; 103(5):591-602. PubMed ID: 8811504
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Evaluation of the early response and mechanism of treatment of Parkinson's disease with L-dopa using
    Fa YH; Ni JQ; Wu XJ; Tan JQ; Wu YW
    Exp Ther Med; 2016 Jan; 11(1):101-109. PubMed ID: 26889225
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Lower CSF homovanillic acid relates to higher burden of neuroinflammation and depression in people with HIV disease.
    Saloner R; Cherner M; Grelotti DJ; Paolillo EW; Moore DJ; Heaton RK; Letendre SL; Kumar A; Grant I; Ellis RJ
    Brain Behav Immun; 2020 Nov; 90():353-363. PubMed ID: 32966871
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Oxidation of dopamine and related catechols in dopaminergic brain regions in Parkinson's disease and during ageing in non-Parkinsonian subjects.
    Fornstedt Wallin B
    J Neural Transm (Vienna); 2024 Mar; 131(3):213-228. PubMed ID: 38238531
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease.
    Pagan FL; Hebron ML; Wilmarth B; Torres-Yaghi Y; Lawler A; Mundel EE; Yusuf N; Starr NJ; Arellano J; Howard HH; Peyton M; Matar S; Liu X; Fowler AJ; Schwartz SL; Ahn J; Moussa C
    Pharmacol Res Perspect; 2019 Apr; 7(2):e00470. PubMed ID: 30906562
    [TBL] [Abstract][Full Text] [Related]  

  • 108. AJ76 and UH232 as potential agents for diagnosing early-stage Parkinson's disease.
    Zhou J; Li J; Papaneri AB; Cui G
    Neuropharmacology; 2023 Mar; 226():109397. PubMed ID: 36623805
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Single-dose L-dopa increases upper brainstem GABA in Parkinson's disease: A preliminary study.
    Song Y; Gong T; Xiang Y; Mikkelsen M; Wang G; Edden RAE
    J Neurol Sci; 2021 Mar; 422():117309. PubMed ID: 33548666
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Circulating cell-free mitochondrial DNA levels in Parkinson's disease are influenced by treatment.
    Lowes H; Pyle A; Santibanez-Koref M; Hudson G
    Mol Neurodegener; 2020 Feb; 15(1):10. PubMed ID: 32070373
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Associations of cerebrospinal fluid monoamine metabolites with striatal dopamine transporter binding and
    Shimasaki R; Kurihara M; Hatano K; Goto R; Taira K; Ihara R; Higashihara M; Nishina Y; Kameyama M; Iwata A
    Parkinsonism Relat Disord; 2024 Nov; 128():107129. PubMed ID: 39241507
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Monoamine Levels and Parkinson's Disease Progression: Evidence From a High-Performance Liquid Chromatography Study.
    Wichit P; Thanprasertsuk S; Phokaewvarangkul O; Bhidayasiri R; Bongsebandhu-Phubhakdi S
    Front Neurosci; 2021; 15():605887. PubMed ID: 34393700
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Gender-Related Differences in the Relationship between Homovanillic Acid in the Cerebrospinal Fluid and Clinical Symptoms in Suicide Attempters.
    Westling S; Ambrus L
    Neuropsychobiology; 2023; 82(3):179-186. PubMed ID: 37062277
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Cerebrospinal fluid levels of proenkephalin and prodynorphin are differentially altered in Huntington's and Parkinson's disease.
    Barschke P; Abu-Rumeileh S; Al Shweiki MHDR; Barba L; Paolini Paoletti F; Oeckl P; Steinacker P; Halbgebauer S; Gaetani L; Lewerenz J; Ludolph AC; Landwehrmeyer GB; Parnetti L; Otto M
    J Neurol; 2022 Sep; 269(9):5136-5143. PubMed ID: 35737109
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Metabolomic profiling to develop blood biomarkers for Parkinson's disease.
    Bogdanov M; Matson WR; Wang L; Matson T; Saunders-Pullman R; Bressman SS; Flint Beal M
    Brain; 2008 Feb; 131(Pt 2):389-96. PubMed ID: 18222993
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Blood D-serine levels correlate with aging and dopaminergic treatment in Parkinson's disease.
    Imarisio A; Yahyavi I; Avenali M; Di Maio A; Buongarzone G; Galandra C; Picascia M; Filosa A; Gasparri C; Monti MC; Rondanelli M; Pacchetti C; Errico F; Valente EM; Usiello A
    Neurobiol Dis; 2024 Mar; 192():106413. PubMed ID: 38253208
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Cerebrospinal fluid levels of chromogranin A in the treatment-naïve early stage Parkinson's disease: a pilot study.
    Kaiserová M; Vranová HP; Stejskal D; Menšíková K; Kaňovský P
    J Neural Transm (Vienna); 2013 Nov; 120(11):1559-63. PubMed ID: 23588348
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Dopaminergic Hyperactivity in Neurological Patients with Delirium.
    Ramírez-Bermúdez J; Perez-Neri I; Montes S; Nente F; Ramirez-Abascal M; Carrillo-Mezo R; Pérez-Esparza R; Soto-Hernandez JL; Espinola-Nadurille M; Bayliss L; De Jesus Flores Rivera J; Rios C
    Arch Med Res; 2019 Nov; 50(8):477-483. PubMed ID: 32018069
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Microfluidic Electrochemical Sensor for Cerebrospinal Fluid and Blood Dopamine Detection in a Mouse Model of Parkinson's Disease.
    Senel M; Dervisevic E; Alhassen S; Dervisevic M; Alachkar A; Cadarso VJ; Voelcker NH
    Anal Chem; 2020 Sep; 92(18):12347-12355. PubMed ID: 32786441
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Elemental fingerprint: Reassessment of a cerebrospinal fluid biomarker for Parkinson's disease.
    Maass F; Michalke B; Willkommen D; Leha A; Schulte C; Tönges L; Mollenhauer B; Trenkwalder C; Rückamp D; Börger M; Zerr I; Bähr M; Lingor P
    Neurobiol Dis; 2020 Feb; 134():104677. PubMed ID: 31733347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.